DexCom (DXCM) Stock Price Down 10%
DexCom, Inc. (NASDAQ:DXCM) shares were down 10% during trading on Thursday . The company traded as low as $51.04 and last traded at $52.25. Approximately 5,951,287 shares changed hands during trading, an increase of 108% from the average daily volume of 2,857,063 shares. The stock had previously closed at $58.08.
A number of research analysts have recently commented on DXCM shares. TheStreet downgraded DexCom from a “c-” rating to a “d+” rating in a research report on Wednesday, October 25th. Wedbush reiterated a “buy” rating and set a $76.00 target price on shares of DexCom in a research report on Wednesday, October 4th. Robert W. Baird reiterated a “hold” rating and set a $79.00 target price on shares of DexCom in a research report on Sunday, September 10th. Barclays started coverage on DexCom in a research report on Friday, September 15th. They set an “equal weight” rating and a $76.00 target price for the company. Finally, Raymond James Financial downgraded DexCom from an “outperform” rating to a “mkt perform” rating in a research report on Friday, September 29th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. DexCom currently has an average rating of “Buy” and a consensus price target of $72.14.
The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84.
Several large investors have recently added to or reduced their stakes in DXCM. Advisor Group Inc. increased its stake in shares of DexCom by 104.9% during the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after buying an additional 837 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of DexCom by 12.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock valued at $238,000 after buying an additional 354 shares during the period. Zions Bancorporation increased its stake in shares of DexCom by 36,222.2% during the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock valued at $160,000 after buying an additional 3,260 shares during the period. Balyasny Asset Management LLC purchased a new position in shares of DexCom during the second quarter valued at $249,000. Finally, Nomura Holdings Inc. purchased a new position in shares of DexCom during the second quarter valued at $262,000.
WARNING: This story was originally posted by Marea Informative and is the property of of Marea Informative. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.mareainformativa.com/2018/01/06/dexcom-dxcm-stock-price-down-10.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.